The twincretin tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.
Newer weight loss drugs are useful tools for patients with obesity, including those who have had bariatric surgery. But debate continues as to how long people should stay on them.
Eli Lilly said on Tuesday all doses of its new diabetes drug Mounjaro were now available with wholesalers having inventory on hand after a 2-month-long shortage.
Weight loss was lower with a GLP-1 agonist than with bariatric surgery, in a small review article and meta-analysis, but researchers have yet to directly compare surgery with new dual or triple agonists.
The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on the complications of obesity, the lead investigator stressed.